BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 10197624)

  • 1. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
    Anderson LD; Petropoulos D; Everse LA; Mullen CA
    Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
    Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease.
    Anderson LD; Savary CA; Mullen CA
    Blood; 2000 Apr; 95(7):2426-33. PubMed ID: 10733517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation.
    Teshima T; Liu C; Lowler KP; Dranoff G; Ferrara JL
    Cancer Res; 2002 Feb; 62(3):796-800. PubMed ID: 11830535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation.
    Teshima T; Mach N; Hill GR; Pan L; Gillessen S; Dranoff G; Ferrara JL
    Cancer Res; 2001 Jan; 61(1):162-71. PubMed ID: 11196155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease.
    Yoshida Y; Hirano T; Son G; Iimuro Y; Imado T; Iwasaki T; Fujimoto J
    Am J Physiol Gastrointest Liver Physiol; 2007 Dec; 293(6):G1114-23. PubMed ID: 17761834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation.
    Korngold R; Leighton C; Manser T
    Transplantation; 1994 Aug; 58(3):278-87. PubMed ID: 7914387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects.
    Moyer JS; Maine G; Mulé JJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1010-9. PubMed ID: 17084367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
    Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
    Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-leukemia effect in allogeneic bone marrow transplantation in mice against several radiation-induced leukemias.
    Aizawa S; Sado T; Kamisaku H; Nemoto K; Yoshida K
    Bone Marrow Transplant; 1994 Feb; 13(2):109-14. PubMed ID: 8205078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
    Hossain MS; Roback JD; Lezhava L; Hillyer CD; Waller EK
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):169-80. PubMed ID: 15744235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
    Har-Noy M; Slavin S
    Med Hypotheses; 2008; 70(6):1186-92. PubMed ID: 18054441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
    Aizawa S; Kamisaku H; Sado T
    Bone Marrow Transplant; 1995 Oct; 16(4):603-9. PubMed ID: 8528179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.